|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, April 11, 2012 ) Los Angeles, CA -- Small Cap Investment Research (SmallCapInvestmentResearch.com), a developer, publisher and marketer of independent research products, announced today the release of an updated research report on Sunpeaks Ventures, Inc (OTCBB: SNPK) (“the Company”). Small Cap Investment Research has issued a “STRONG BUY” and a target price of $9.00 on shares of this company.
The report examines the potential continued growth of the Company as it continues to gain market share, and examines the outlook for short and long-term investors. “We were pleased to have the opportunity to report on this company and the industry factors that affect it. The report presents a great overview of the Company and its potential for the long-term with a constantly improving industry dynamic.” – Small Cap Investment Research.
Recently, Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") announced that HDS has signed a Letter of Intent with PharmaLife® for placement of Clotamin® with leading pharmacies in the Russian Federation.
The Letter of Intent outlines the terms and conditions of a proposed transaction that could see Clotamin distributed by several pharmacy and retail chains in the Russian Federation, including product placement with leading wholesalers Imperia-Pharma, the Dr. Stoletov pharmacy chain (414 locations), and other small retail pharmacies associated with Imperia-Pharma. PharmaLife is also expected to secure timely product registration within the Russian Federation for Clotamin distribution and conduct local market research to support a successful product launch.
The entire report can be found on http://www.smallcapinvestmentresearch.com/featured-companies/ .
About Small Cap Investment Research:
Small Cap Investment Research specializes in providing readers with an in-depth analysis of undervalued companies. The company’s role as an independent research analyst firm is to “separate the wheat from the chaff” and help investors receive unbiased, thought-provoking, and quality investment research. SCIR’s philosophy in research is to encapsulate realistic investment ratings, target prices, and forward-looking financial models. The reports contain hard-hitting, meticulously researched facts on companies, their fundamentals, and their industries, validating a company’s prospects and enabling the reader to objectively evaluate the company’s value. The media and savvy investors alike view this model as how investment research needs to be performed devoid of any partiality.
About Sunpeaks Ventures, Inc.:
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
Forward-Looking Statements
Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of Sunpeaks Ventures, Inc. (OTCBB: SNPK) can be found in the filings of Sunpeaks Ventures, Inc. with the U.S. Securities and Exchange Commission.
Release of Liability: Through use of this website viewing or using you agree to hold SCIR, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. We have been compensated six thousand dollars for this SNPK report. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCIR encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCIR makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies.
Indepedent Research Investment
Derrick Brazinski
3104567798
dbrazinski@indedentresearchinvestment.com 
Source: EmailWire.com
|
|
|
|
